RxDoctor Payments Data

Katelyn Hammrich, PA

Physician Assistant · Plummer, IDNPI 1003463902

Payments from drug & device makers

$3,726in general payments, 2019–2025

Across 217 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$695
  • GSK$543
  • Lilly USA, LLC$416
  • Pfizer$223
  • AstraZeneca$184
  • Amgen$167
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,726 in reported general payments places this provider in the 90th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$90,397
Medicare patients
249
Services billed
1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide52$65,112
OzempicSemaglutide55$65,076
FarxigaDapagliflozin Propanediol48$49,723
JardianceEmpagliflozin14$24,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,284
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$15,735
KerendiaFinerenone16$15,617
RybelsusSemaglutide13$14,779
Repatha PushtronexEvolocumab16$9,467
Soliqua 100-33Insulin Glargine/Lixisenatide13$6,037
DayvigoLemborexant16$5,443
Arnuity ElliptaFluticasone Furoate19$4,951
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,694
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,687
Atorvastatin Calcium198$2,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$166$79,85468 claims
Lilly USA, LLCTrulicity$416$65,11252 claims
AstraZenecaFarxiga$184$49,72348 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$543$39,97062 claims
Boehringer IngelheimJardiance$95$24,75814 claims
BayerKerendia$107$15,61716 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$100$6,03713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Plummer

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →